Targeting Peroxisome Proliferator-activated Receptor-gamma in Peritoneal Dialysis Patients - Will it Reduce Inflammation, Atherosclerosis, Calcification and Improve Survival of Peritoneal Dialysis Patients?
Both prevalent patients or patients newly started on continuous ambulatory peritoneal dialysis with age between 20 - 75 with or without diabetes mellitus will be considered eligible for study entry. For patients newly started on continuous ambulatory peritoneal dialysis, they will be suitable for recruitment into the study after one month on continuous ambulatory peritoneal dialysis.
You may not be if
Patients with underlying malignancy
Patients with chronic liver disease or liver cirrhosis
Patients with hepatitis B or C positive
Patients with active infections
Patients with other chronic active inflammatory disease such as systemic lupus erythematosus, rheumatoid arthritis
Patients who refuse study participation
Patients with underlying congenital heart disease or rheumatic heart disease
Patients with poor general condition
Patients with plans for living related kidney transplant within 2 years
Female patients with pregnancy
Patients with history of recurrent hypoglycemia
Patients with Class III and IV congestive heart failure
Patients already receiving glitazones treatment at the screening visit
Clareo Health | Targeting Peroxisome Proliferator-activated Receptor-gamma in Peritoneal Dialysis Patients - Will it Reduce Inflammation, Atherosclerosis, Calcification and Improve Survival of Peritoneal Dialysis Patients?
